Surgical Endoscopy

, Volume 23, Issue 5, pp 1161–1163

Advanced gastric cancer: is laparoscopic gastrectomy safe?



  1. 1.
    Ryu KW, Kim YW, Lee JH (2008) Surgical complications and the risk factors of laparoscopy-assisted distal gastrectomy in early gastric cancer. Ann Surg Oncol 15:1625–1631PubMedCrossRefGoogle Scholar
  2. 2.
    Hwang SI, Kim HO, Yoo CH, Shin JH, Son BH (2008) Laparoscopic-assisted distal gastrectomy versus open distal gastrectomy for advanced gastric cancer. Surg Endosc. Epub ahead of printGoogle Scholar
  3. 3.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406PubMedCrossRefGoogle Scholar
  4. 4.
    Lee JH, Kim YW, Ryu KW (2007) A phase II clinical trial of laparoscopy-assisted distal gastrectomy with d2 lymph node dissection for gastric cancer patients. Ann Surg Oncol 14:3148–3153PubMedCrossRefGoogle Scholar
  5. 5.
    The Japan Clinical Oncology Group, Sasako M, Sano T, Yamamoto S et al (2008) D2 lymphadenectomy alone or with paraaortic nodal dissection for gastric cancer. N Engl J Med 359:453–462PubMedCrossRefGoogle Scholar
  6. 6.
    Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820PubMedCrossRefGoogle Scholar
  7. 7.
    Liakakos T, Roukos DH (2008) More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15:956–960PubMedCrossRefGoogle Scholar
  8. 8.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129PubMedCrossRefGoogle Scholar
  9. 9.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9:828–830PubMedCrossRefGoogle Scholar
  10. 10.
    Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123:573–578PubMedCrossRefGoogle Scholar
  11. 11.
    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221PubMedCrossRefGoogle Scholar
  13. 13.
    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939PubMedCrossRefGoogle Scholar
  14. 14.
    Punglia RS, Morrow M, Winer EP et al (2007) Local therapy and survival in breast cancer. N Engl J Med 356:2399–2440PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast conservation therapy for breast cancer. Ann Surg Oncol 10:718–721PubMedCrossRefGoogle Scholar
  16. 16.
    Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5:737–745PubMedCrossRefGoogle Scholar
  17. 17.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRefGoogle Scholar
  18. 18.
    Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357:283–291PubMedCrossRefGoogle Scholar
  19. 19.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715PubMedCrossRefGoogle Scholar
  20. 20.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556 author reply 1556PubMedCrossRefGoogle Scholar
  21. 21.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33PubMedCrossRefGoogle Scholar
  22. 22.
    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9:941–943PubMedGoogle Scholar
  23. 23.
    Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11:1030–1034PubMedCrossRefGoogle Scholar
  24. 24.
    Manolio TA, Brooks LD, Collins FS (2008) A HapMap harvest of insights into the genetics of common disease. J Clin Invest 18:1590–1605CrossRefGoogle Scholar
  25. 25.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8:587–597PubMedCrossRefGoogle Scholar
  26. 26.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361PubMedCrossRefGoogle Scholar
  27. 27.
    Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8:29–39PubMedCrossRefGoogle Scholar
  28. 28.
    Huang CC, Bredel M (2008) Use of gene signatures to improve risk estimation in cancer. JAMA 299:1605–1606PubMedCrossRefGoogle Scholar
  29. 29.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197–198PubMedCrossRefGoogle Scholar
  30. 30.
    Roukos DH (2008) Breast cancer stromal cells with TP53 mutations. N Engl J Med 358:1636PubMedCrossRefGoogle Scholar
  31. 31.
    Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159PubMedCrossRefGoogle Scholar
  32. 32.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6PubMedCrossRefGoogle Scholar
  33. 33.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798PubMedCrossRefGoogle Scholar
  34. 34.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338PubMedCrossRefGoogle Scholar
  35. 35.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773PubMedCrossRefGoogle Scholar
  36. 36.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? Ann Surg Oncol 16(3):774–775PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Third Surgical DepartmentUniversity of AthensAthensGreece

Personalised recommendations